SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 2168696

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 2168696

BK virus (BKV) Infection - Market Insight, Epidemiology, and Market Forecast - 2036

PUBLISHED:
PAGES: 229 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 7990
PDF & Excel (2-3 User License)
USD 9988
PDF & Excel (Site License)
USD 13983
PDF & Excel (Global License)
USD 17978

Add to Cart

BK Virus infection Insights and Trends

  • The BKV infection market across the 7MM is anticipated ~USD 35 million in 2025, representing a CAGR of approximately 45%. Market expansion is expected to be driven by the anticipated entry of disease-specific therapies for BK DNAemia/BKPyVAN and BKHC, increasing diagnosis.
  • BK virus infection represents a concentrated, high-value opportunity, primarily driven by BK virus-associated nephropathy (BKVAN) in kidney transplant recipients and BK virus-associated hemorrhagic cystitis (BKHC) in HSCT recipients, with commercial success dependent on targeting high-risk patients and demonstrating meaningful renal or clinical outcomes.
  • Although BKPyV is also clinically relevant in Hematopoietic Stem Cell Transplantation (HSCT), particularly in BKPyV-associated hemorrhagic cystitis, the most mature epidemiological and therapeutic evidence base remains concentrated in kidney transplantation.
  • The diagnosed prevalent cases of BKV infection in the US are estimated at ~4,300 cases in 2025, representing the largest patient share among the 7MM. The higher diagnosed burden in the US may reflect its large transplant population, greater availability of routine BKV PCR-based surveillance, and broader recognition of BKV infection in immunocompromised patients, particularly kidney transplant recipients.
  • Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~480 cases, followed by Class 1 at ~300 cases and Class 3 at ~100 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.
  • The National Kidney Federation reports that approximately 20% of kidney transplant recipients develop BKV DNAemia, of whom around 25% progress to BK nephropathy (BKVAN); accordingly, a 25% progression rate was applied to the estimated BKV DNAemia/viremia population to derive BKVAN cases.
  • In Japan, Grade 2 emerged as the leading severity level for HSCT-associated BKHC cases, accounting for ~400 cases in 2025, followed by Grade 3 at ~300 cases, while Grade 1 and Grade 4 remained equal at ~110 cases each.
  • The current BKV treatment market is dominated by off-label, non-specific approaches, with IVIG, cidofovir, leflunomide, and fluoroquinolones (ciprofloxacin/levofloxacin) forming the core treatment landscape for both BKVAN and BKHC. The absence of an approved, virus-directed therapy creates a highly fragmented market with substantial unmet need.

BK Virus infection Market size and forecast

  • 2025 BK Virus Infection Market Size in the 7MM: ~USD 35 million
  • BK Virus Infection Growth Rate (2026-2036) in the 7MM: 45% CAGR

DelveInsight's 'BK Virus Infection - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of BK virus infection, historical and forecasted epidemiology, as well as the BK virus infection market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The BK virus infection market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, BK virus infection patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in BK virus infection and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

BK Virus Infection Understanding and Treatment Algorithm

BK Virus Infection Overview and Diagnosis

BK virus (BKPyV), also known as a human polyomavirus, is a common virus that is typically acquired during childhood. Primary infection is usually asymptomatic or causes mild cold-like symptoms. After the initial infection, the virus remains latent for life in the kidneys and the epithelial lining of the ureters and urinary bladder. In healthy individuals, the immune system generally keeps the virus in a dormant state. However, when immune function is suppressed, BKV may reactivate and cause clinically significant infection. Reactivation occurs most commonly in kidney transplant recipients, who require long-term immunosuppressive therapy to prevent graft rejection. Active BKV infection can involve the kidneys, ureters, and bladder and may lead to renal injury.

The diagnosis of BKV infection relies on a combination of complementary laboratory and histopathological techniques, selected based on the clinical setting, the urgency of evaluation, and the available diagnostic infrastructure. Initial assessment typically includes quantitative polymerase chain reaction (PCR) testing for BK viral DNA in urine and plasma, with viruria serving as an early marker of viral reactivation and persistent viremia indicating an increased risk of BKVAN.

BK Virus Infection Treatment Landscape

Overall, the BK virus infection treatment landscape remains highly fragmented, with no single therapy delivering consistent, long-term viral control or protection against graft dysfunction across patients. Despite broad use of off-label antiviral and immunosuppression-modulating strategies, real-world experience indicates that many patients remain undertreated, cycle through multiple regimens, or discontinue therapy due to limited efficacy, tolerability concerns, or viremia recurrence. The complete absence of any FDA, EMA, PMDA, or MHRA-approved drug specifically for BK virus infection sustains this fragmentation and continues to drive demand for simpler, more durable, and biologically targeted approaches that can move beyond cyclic symptomatic management.

DelveInsight anticipates changes in the treatment landscape for BK virus infection over the coming years, driven by emerging therapy Potravitug from Ipsen/ Memo Therapeutics, which is projected to enter the market and has the potential to significantly influence future treatment strategies.

BK Virus Infection Unmet Needs

The section "unmet needs of BK virus infection" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Reliance on immunosuppression reduction leaves a fundamental treatment gap

2. Viral replication is common, but clinically meaningful disease remains difficult to predict and intercept

3. Current management can control the virus at the cost of increased immunological risk

4. Epidemiological and clinical evidence remains disproportionately concentrated in kidney transplantation

5. Epidemiological estimates remain heterogeneous, limiting precise assessment of the addressable population

BK Virus Infection Epidemiology

Key Findings from BK Virus Infection Epidemiological Analysis and Forecast

  • The total number of BKVAN cases across the 7MM is expected to increase from approximately 4000 cases in 2025, primarily reflecting the growing kidney transplant population, continued exposure to immunosuppressive therapy, and improved screening and surveillance for BKPyV DNAemia among kidney transplant recipients.
  • The diagnosed prevalent cases of BKV infection in the US are estimated at 4,300 cases in 2025, representing the largest patient share among the 7MM.
  • In 2025, Japan was estimated to have approximately 925 cases of BKHC, reflecting the addressable patient population within the country's allogeneic HSCT setting.
  • Class 2 BKVAN represents the predominant disease segment, accounting for approximately 55% of total BKVAN cases across the 7MM, highlighting this subgroup as a key focus of the addressable patient population and a potentially important target for emerging disease-specific therapies.
  • Among grade-specific BKHC cases in the US, Grade 2 was the predominant category, accounting for approximately 44% of cases, followed by Grade 3, indicating that a substantial proportion of patients present with moderate-to-severe disease.

BK Virus Infection Drug Analysis & Competitive Landscape

The BK virus infection drug chapter provides a detailed, market-focused review of emerging pipeline across mid and late Phase clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the BK virus infection treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the BK virus infection therapeutics market.

BK Virus Infection Pipeline Analysis

Potravitug: Ipsen/ Memo Therapeutics

Potravitug is an investigational fully human IgG1-kappa monoclonal antibody targeting the VP1 major capsid protein of BK polyomavirus (BKPyV). By binding to VP1, potravitug blocks viral attachment and entry into host cells, thereby neutralizing BKPyV across all four known serotypes. The therapy is being developed as a targeted treatment for BKPyV infection in kidney transplant recipients, with the potential to reduce viral replication while avoiding the need for extensive reduction of immunosuppression.

  • Currently in Phase II/III reporting sustained reductions in BKPyV viral load and resolution of biopsy-proven BKPyV-associated nephropathy through Week 38.
  • The US FDA and European Commission granted Fast Track and Orphan Drug designations, respectively, to potravitug (AntiBKV) for the treatment of BKPyV infection in kidney/renal transplant recipients, underscoring the significant unmet need and absence of approved targeted therapies for this population.

BK virus infection Key Players, Market Leaders and Emerging Companies

  • Ipsen
  • Memo Therapeutics
  • Vera Therapeutics
  • LucasBio
  • SymBio Pharmaceuticals

BK Virus Infection Drug Updates

  • In June 2026, Memo Therapeutics presented the complete Phase II SAFE KIDNEY II dataset at the American Transplant Congress 2026, reporting sustained reductions in BKPyV viral load and resolution of biopsy-proven BKPyV-associated nephropathy through week 38.
  • In April 2026, Asahi Kasei completed its acquisition of AiCuris, bringing AIC468 into its pharmaceutical pipeline with deal value of USD 920 million. AIC468 had completed Phase I and was being developed for BKV infection in kidney transplant and hematopoietic stem cell transplant recipients, with Asahi Kasei planning to advance its development through its US subsidiary Veloxis Pharmaceuticals.

BK Virus Infection Market Outlook

The market outlook for BK virus infection remains encouraging, driven by its rare disease designation, high unmet clinical need, and growing awareness leading to earlier diagnosis. Current care is largely symptomatic and centers on modulating immunosuppression, aimed at controlling viral replication and preventing graft injury rather than directly targeting the underlying viral biology. No drug is specifically approved for BK virus infection in the US (FDA), EU (EMA), UK (MHRA), or Japan (PMDA); pharmacological management relies entirely on off-label use of antiviral agents, immunosuppression reduction strategies, and other regionally accepted supportive approaches.

Overall, in BK virus infection, the launch of targeted therapies, improved diagnosis through advanced neuroimaging and biomarker-based assessments, and increasing disease awareness are expected to drive steady growth in the 7MM BK virus infection market from 2025-2036, with strong commercial implications for emerging pipelines.

  • In 2025, the BK virus infection market in the US was estimated at approximately ~USD 15 million, representing the dominant share of around 55% of the total 7MM market.
  • In 2025, EU4 and the UK collectively contributed approximately ~USD 14.5 million to the BK virus infection market, accounting for around 30% of the total 7MM revenues.
  • In 2025, Japan accounted for approximately ~USD 5 million in BK virus infection market revenues, representing a ~20% share of the total 7MM market.
  • A notable recent shift in the treatment landscape is the gradual expansion of the pipeline, with emerging agents such as Potravitug, AIC468, MAU868, LB-DTK-BKV, and LB-DTK-MV. These investigational therapies are anticipated to play a pivotal role in transforming future management approaches by targeting underlying BK virus infection.

Drug Class/Insights into Leading Emerging Therapies in BK Virus Infection (2022-2036 Forecast)

The treatment landscape of BK virus infection remains highly limited and is driven primarily by immune modulation rather than direct antiviral therapy. In kidney transplantation, the standard approach is stepwise reduction or modification of immunosuppressive therapy. In HSCT recipients with BKPyV-HC, management is predominantly supportive, including hydration, analgesia, bladder irrigation, transfusion support, and urologic intervention when required.

Off-label and investigational approaches, including cidofovir, leflunomide, fluoroquinolones, IVIG, and virus-specific T-cell therapy, have been explored for BKPyV infection, but clinical evidence remains limited or inconsistent, and none has established a definitive antiviral standard of care. Current consensus guidelines recommend reduction of immunosuppression as the primary treatment for persistent BKPyV-DNAemia or BKPyV nephropathy in kidney transplant recipients, while cidofovir, leflunomide, and fluoroquinolones are not recommended for routine use; IVIG may be considered as an adjunct in selected patients. No antiviral therapy is currently approved specifically for BKPyV infection, BKPyV-DNAemia, or BKPyV nephropathy.

Intravenous immunoglobulin (IVIG)

IVIG has been investigated as an adjunctive treatment for BKPyV infection because pooled immunoglobulin preparations contain high titers of BKPyV-neutralizing antibodies and may provide immunomodulatory effects.

Cidofovir

Cidofovir has demonstrated in vitro activity against BKPyV and has historically been used off-label in patients with persistent or severe infection.

Leflunomide

Leflunomide has historically been used off-label in BKVAN because its active metabolite has demonstrated potential anti-BKPyV activity in vitro in addition to its immunosuppressive effects.

Fluoroquinolones

Fluoroquinolones, including ciprofloxacin and levofloxacin, have been investigated because of their proposed inhibitory effects on BKPyV replication.

BK Virus Infection Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the BK virus infection drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Based on the anticipated uptake rates, potravitug is expected to demonstrate a medium-to-fast uptake trajectory across the 7MM within the BKVAN/BK-DNAemia segment, reflecting its more advanced development stage and the regulatory support it has received through Fast Track and Orphan Drug designations. In contrast, MAU868 and AIC468 are projected to see medium uptake across all markets, consistent with their comparatively earlier positioning and the presence of a competing, more differentiated asset. Within the BK-HC segment, both LB-DTK-BKV and LB-DTK-MV are similarly expected to achieve medium uptake uniformly across the 7MM. Overall, potravitug is positioned to be the fastest-adopted therapy among these emerging candidates, while the remaining pipeline assets are anticipated to follow a steadier, more gradual uptake pattern as clinical experience and physician familiarity build over time.

Detailed insights of emerging therapies' drug uptake is included in the report.

Industry Experts and Physician Views for BK Virus Infection

To keep up with BK virus infection market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the BK virus infection emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts engaged with 40+ key opinion leaders (KOLs) across major markets to capture country-level insights in BK virus infection Leading centers such as University of California and Royal College of Physicians, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate emerging BK virus infection, therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for Market access, therapy adoption, and pipeline prioritization in BK virus infection.

Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of BK virus infection, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts systematically evaluates promising emerging therapies based on a set of relevant attributes, including safety, efficacy, frequency of administration, route of administration, and order of market entry. Efficacy is assessed primarily through the trial's stated primary and secondary outcome measures, providing a clinically grounded basis for comparing therapeutic potential across candidates. Safety is evaluated in parallel, with particular emphasis on acceptability, tolerability, and the nature and frequency of adverse events reported during clinical development, as these factors directly influence real-world adoption and patient retention on therapy.

Beyond clinical performance, the scoring framework also incorporates practical and commercial considerations, including the route of administration (which affects convenience and patient preference), order of entry into the market (which shapes competitive positioning relative to existing and pipeline therapies), probability of technical and regulatory success, and the addressable patient pool that each therapy is positioned to serve. Each of these parameters is assigned a relative weightage reflecting its expected influence on commercial performance and clinical adoption.

Scope of the Report:

  • The report covers a segment of key events, an executive summary, a descriptive overview of BK virus infection, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
  • Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
  • A detailed review of the BK virus infection market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM BK virus infection market.

Report Insight

  • BK Virus Infection Therapeutics Market Size
  • BK Virus Infection Patient Population Forecast
  • BK Virus Infection Pipeline Analysis
  • BK Virus Infection Market Size and Trends
  • BK Virus Infection Market Opportunity (Current and forecasted)

Report Key Strengths

  • Epidemiology-Based (Epi-based) Bottom-up Forecasting
  • Artificial Intelligence (AI)-enabled Market Research Report
  • 11-year forecast

BK virus infection Market Outlook (North America, Europe, Asia-Pacific)

  • Patient Burden Trends (by geography)
  • BK Virus Infection Treatment Addressable Market (TAM)
  • BK Virus Infection Competitive Landscape
  • BK Virus Infection Major Companies Insights
  • BK Virus Infection Price Trends and Analogue Assessment
  • BK Virus Infection Therapies Drug Adoption/Uptake
  • BK Virus Infection Therapies Peak Patient Share Analysis

Report Assessment

  • BK Virus Infection Current Treatment Practices
  • BK Virus Infection Unmet Needs
  • BK Virus Infection Clinical Development Analysis
  • BK Virus Infection Emerging Drugs Product Profiles
  • BK Virus Infection Market Attractiveness
  • BK Virus Infection Qualitative Analysis (SWOT and Attribute Analysis FAQs)

Market Insights

  • What was the BK virus infection market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
  • What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
  • What can be the future treatment paradigm of BK virus infection?
  • What are the disease risks, burdens, and unmet needs of BK virus infection? What will be the growth opportunities across the 7MM concerning the patient population with BK virus infection?
  • Who is the major future competitor in the market, and how will the competitors affect their market share?
  • What are the current options for the treatment of BK virus infection?
  • What are the current guidelines for treating BK virus infection in the US, Europe, and Japan?

Reasons to Buy:

  • The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the BK virus infection market.
  • Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
  • Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
  • Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
  • Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
  • To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
  • This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.
Product Code: DIMI0704

Table of Contents

1. Key Insights

2. Report Introduction

3. BK Virus Infection Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of BK Virus Infection by Therapies in the 7MM in 2025
  • 3.2. Market Share (%) Distribution of BK Virus Infection by Therapies in the 7MM in 2036

4. Executive Summary

5. Key Events

6. Disease Background and Overview: BK Virus Infection

  • 6.1. Types of BKV Infection
  • 6.2. Causes and Risk Factors of BK Virus Infection
    • 6.2.1. Risk Factors
  • 6.3. Pathophysiology of BKV Infection
  • 6.4. Etiology of BKV Infection
  • 6.5. Diagnosis of BKV Infection
  • 6.6. Diagnostic Algorithm
    • 6.6.1. Differential Diagnosis
  • 6.7. Diagnostic Guidelines
    • 6.7.1. The Second International Consensus Guidelines on the Assessment of BK Polyomavirus in Kidney Transplantation, 2024
    • 6.7.2. American Society of Transplantation Infectious Diseases Community of Practice Clinical Transplantation, 2019
    • 6.7.3. Clinical Journal of American Society of Nephrology, 2018
    • 6.7.4. UK Guideline on Management of BK Polyomavirus (BKPyV) Infection and Disease Following Kidney Transplantation, 2024
    • 6.7.5. European Conference on Infections in Leukemia (ECIL-6) Guidelines, 2018
  • 6.8. Treatment of BKV Infection
  • 6.9. Treatment Algorithm
  • 6.10. Treatment Guidelines
    • 6.10.1. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation, 2024
    • 6.10.2. American Society of Transplantation Infectious Diseases Community of Practice Clinical Transplantation, 2019
    • 6.10.3. Clinical Journal of American Society of Nephrology, 2018
    • 6.10.4. UK Guideline on Management of BK Polyomavirus (BKPyV) Infection and Disease Following Kidney Transplantation, 2024
    • 6.10.5. European Conference on Infections in Leukemia (ECIL-6) guidelines, 2018

7. Epidemiology and Market Methodology

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumptions and Rationale: 7MM
    • 8.2.1. United States
    • 8.2.2. EU4 and the UK
      • 8.2.2.1. Germany
      • 8.2.2.2. France
      • 8.2.2.3. Italy
      • 8.2.2.4. Spain
      • 8.2.2.5. United Kingdom
    • 8.2.3. Japan
  • 8.3. Total Cases of HSCT in the 7MM
  • 8.4. Total Cases of Kidney Transplant in the 7MM
  • 8.5. Total Cases of BKV Infection in the 7MM
  • 8.6. Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM
  • 8.7. Total Cases of BKVAN in the 7MM
  • 8.8. Total Cases of BKHC in the 7MM
  • 8.9. The US
    • 8.9.1. Total Cases of BK Viremia in Kidney Transplant Patients in the US
    • 8.9.2. Total Cases of BKVAN in the US
    • 8.9.3. Classification-specific Cases of BKVAN in the US
    • 8.9.4. Type-specific HSCT Cases in the US
    • 8.9.5. Total Cases of BKHC in the US
    • 8.9.6. Grade-specific Cases of BKHC in the US
  • 8.10. EU4 and the UK
    • 8.10.1. Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK
    • 8.10.2. Total Cases of BKVAN in EU4 and the UK
    • 8.10.3. Classification-specific Cases of BKVAN in EU4 and the UK
    • 8.10.4. Type-specific HSCT Cases in EU4 and the UK
    • 8.10.5. Total Cases of BKHC in EU4 and the UK
    • 8.10.6. Grade-specific Cases of BKHC in EU4 and the UK
  • 8.11. Japan
    • 8.11.1. Total Cases of BK Viremia in Kidney Transplant Patients in Japan
    • 8.11.2. Total Cases of BKVAN in Japan
    • 8.11.3. Classification-specific Cases of BKVAN in Japan
    • 8.11.4. Type-specific HSCT Cases in Japan
    • 8.11.5. Total Cases of BKHC in Japan
    • 8.11.6. Grade-specific Cases of BKHC in Japan

9. Patient Journey

10. Emerging Drugs

  • 10.1. Competition Landscape of Emerging Drugs
  • 10.2. Potravitug: Ipsen/ Memo Therapeutics
    • 10.2.1. Product Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
      • 10.2.3.1. Clinical Trial Information
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Analyst Views
  • 10.3. MAU868: Vera Therapeutics
    • 10.3.1. Product Description
    • 10.3.2. Other Developmental activities
    • 10.3.3. Clinical Development
      • 10.3.3.1. Clinical Trial Information
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Analyst view
  • 10.4. AIC468: AiCuris / Veloxis Pharmaceuticals
    • 10.4.1. Product Description
    • 10.4.2. Other Developmental activities
    • 10.4.3. Clinical Development
      • 10.4.3.1. Clinical Trial Information
    • 10.4.4. Safety and Efficacy
    • 10.4.5. Analyst view
  • 10.5. LB-DTK-BKV: LucasBio
    • 10.5.1. Product Description
    • 10.5.2. Other Developmental activities
    • 10.5.3. Clinical Development
      • 10.5.3.1. Clinical Trial Information
    • 10.5.4. Analyst view
  • 10.6. LB-DTK-MV: LucasBio
    • 10.6.1. Product Description
    • 10.6.2. Other Developmental activities
    • 10.6.3. Clinical Development
      • 10.6.3.1. Clinical Trial Information
    • 10.6.4. Analyst view

11. BK Virus Infection: The 7MM Analysis

  • 11.1. Key Findings
  • 11.2. Market Outlook
  • 11.3. Attribute Analysis
  • 11.4. Key Market Forecast Assumptions
    • 11.4.1. Cost Assumptions and Rebates
    • 11.4.2. Pricing Trends
    • 11.4.3. Analogue Assessment
    • 11.4.4. Launch Year and Therapy Uptake
  • 11.5. Total market size of BKV Infection in the 7MM
  • 11.6. Total market size of BKVAN in the 7MM
  • 11.7. Market Size of BKVAN by Therapies in the 7MM
  • 11.8. Total market size of BKHC in the 7MM
  • 11.9. Market Size of BKHC by Therapies in the 7MM
  • 11.10. The United States Market Size
    • 11.10.1. Total Market Size of BKVAN in the US
    • 11.10.2. Market Size of BKVAN by Therapies in the US
    • 11.10.3. Total Market Size of BKHC in the US
    • 11.10.4. Market Size of BKHC by Therapies in the US
  • 11.11. EU4 and the UK Market Size
    • 11.11.1. Total Market Size of BKVAN in EU4 and the UK
    • 11.11.2. Market Size of BKVAN by Therapies in EU4 and the UK
    • 11.11.3. Total Market Size of BKHC in EU4 and the UK
    • 11.11.4. Market Size of BKHC by Therapies in EU4 and the UK
  • 11.12. Japan Market Size
    • 11.12.1. Total Market Size of BKVAN in Japan
    • 11.12.2. Market Size of BKVAN by Therapies in Japan
    • 11.12.3. Total Market Size of BKHC in Japan
    • 11.12.4. Market Size of BKHC by Therapies in Japan

12. Unmet Needs

13. SWOT Analysis

14. KOL Views

15. Market Access and Reimbursement

  • 15.1. The United States
  • 15.2. EU4 and the UK
    • 15.2.1. Germany
    • 15.2.2. France
    • 15.2.3. Italy
    • 15.2.4. Spain
  • 15.3. United Kingdom
  • 15.4. Japan
  • 15.5. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

16. Appendix

  • 16.1. Bibliography
  • 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Product Code: DIMI0704

List of Tables

  • Table 1: Summary of BKV Infection Epidemiology and Market (2025-2036)
  • Table 2: BKV Screening Methods
  • Table 3: Recommendation monitoring schedule
  • Table 4: Diagnosis and monitoring
  • Table 5: Screening Methods for BKPyV-HC
  • Table 6: Grading systems used at ECIL-6 for levels of evidence and strength of recommendations
  • Table 7: Treatment and management
  • Table 8: Management of BK polyomavirus-associated hemorrhagic cystitis (BKPyV-HC)
  • Table 9: Grading systems used at ECIL-6 for levels of evidence and strength of recommendations
  • Table 10: Total Cases of HSCT in the 7MM (2022-2036)
  • Table 11: Total Cases of Kidney Transplant in the 7MM (2022-2036)
  • Table 12: Total Cases of BKV Infection in the 7MM (2022-2036)
  • Table 13: Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM (2022-2036)
  • Table 14: Total Cases of BKVAN in the 7MM (2022-2036)
  • Table 15: Total Cases of BKHC in the 7MM (2022-2036)
  • Table 16: Total Cases of BK Viremia in Kidney Transplant Patients in the US (2022-2036)
  • Table 17: Total Cases of BKVAN in the US (2022-2036)
  • Table 18: Classification-specific Cases of BKVAN in the US (2022-2036)
  • Table 19: Type-specific HSCT Cases in the US (2022-2036)
  • Table 20: Total Cases of BKHC in the US (2022-2036)
  • Table 21: Grade-specific Cases of BKHC in the US (2022-2036)
  • Table 22: Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK (2022-2036)
  • Table 23: Total Cases of BKVAN in EU4 and the UK (2022-2036)
  • Table 24: Classification-specific Cases of BKVAN in EU4 and the UK (2022-2036)
  • Table 25: Type-specific HSCT Cases in EU4 and the UK (2022-2036)
  • Table 26: Total Cases of BKHC in EU4 and the UK (2022-2036)
  • Table 27: Grade specific cases of BKHC in EU4 and the UK (2022-2036)
  • Table 28: Total Cases of BK Viremia in Kidney Transplant Patients in Japan (2022-2036)
  • Table 29: Total Cases of BKVAN in Japan (2022-2036)
  • Table 30: Classification-specific Cases of BKVAN in Japan (2022-2036)
  • Table 31: Type-specific HSCT Cases in Japan (2022-2036)
  • Table 32: Total Cases of BKHC in Japan (2022-2036)
  • Table 33: Grade-specific Cases of BKHC in Japan (2022-2036)
  • Table 34: Comparison of Emerging Drugs Under Development for BKV Infection
  • Table 35: Potravitug, Clinical Trial Description, 2026
  • Table 36: MAU868, Clinical Trial Description, 2026
  • Table 37: AIC468, Clinical Trial Description, 2026
  • Table 38: LB-DTK-BKV, Clinical Trial Description, 2026
  • Table 39: LB-DTK-MV, Clinical Trial Description, 2026
  • Table 40: Key Market Forecast Assumptions of BKV Infections in the United States
  • Table 41: Key Market Forecast Assumptions of BKV Infections in EU4 and the UK
  • Table 42: Key Market Forecast Assumptions of BKV Infections in Japan
  • Table 43: Total market size of BKHC in the 7MM, in USD million (2022-2036)
  • Table 44: Market Size of BKHC by Therapies in the 7MM, in USD million (2022-2036)
  • Table 45: Total Market Size of BKVAN in the US, in USD million (2022-2036)
  • Table 46: Market Size of BKVAN by Therapies in the US, in USD million (2022-2036)
  • Table 47: Total Market Size of BKHC in the US, in USD million (2022-2036)
  • Table 48: Market Size of BKHC by Therapies in the US, in USD million (2022-2036)
  • Table 49: Total Market Size of BKVAN in EU4 and the UK, in USD million (2022-2036)
  • Table 50: Market Size of BKVAN by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Table 51: Total Market Size of BKHC in EU4 and the UK, in USD million (2022-2036)
  • Table 52: Market Size of BKHC by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Table 53: Total Market Size of BKVAN in Japan, in USD million (2022-2036)
  • Table 54: Market Size of BKVAN by Therapies in Japan, in USD million (2022-2036)
  • Table 55: Total Market Size of BKHC in Japan, in USD million (2022-2036)
  • Table 56: Market Size of BKHC by Therapies in Japan, in USD million (2022-2036)

List of Figures

  • Figure 1: Clinical Manifestations of BKV Infection
  • Figure 2: Sign and Symptoms of BKV Infection
  • Figure 3: Pathophysiology of BKV Infection
  • Figure 4: Diagnosis of BKV Infection
  • Figure 5: Diagnostic Algorithm of BKV Infection (Renal Transplantation)
  • Figure 6: Diagnostic Algorithm of BKV Infection
  • Figure 7: Treatment Algorithm of BKV Infection
  • Figure 8: Total Cases of HSCT in the 7MM (2022-2036)
  • Figure 9: Total Cases of Kidney Transplant in the 7MM (2022-2036)
  • Figure 10: Total Cases of BKV Infection in the 7MM (2022-2036)
  • Figure 11: Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM (2022-2036)
  • Figure 12: Total Cases of BKVAN in the 7MM (2022-2036)
  • Figure 13: Total Cases of BKHC in the 7MM (2022-2036)
  • Figure 14: Total Cases of BK Viremia in Kidney Transplant Patients in the US (2022-2036)
  • Figure 15: Total Cases of BKVAN in the US (2022-2036)
  • Figure 16: Classification-specific Cases of BKVAN in the US (2022-2036)
  • Figure 17: Type-specific HSCT Cases in the US (2022-2036)
  • Figure 18: Total Cases of BKHC in the US (2022-2036)
  • Figure 19: Grade-specific Cases of BKHC in the US (2022-2036)
  • Figure 20: Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK (2022-2036)
  • Figure 21: Total Cases of BKVAN in EU4 and the UK (2022-2036)
  • Figure 22: Classification-specific Cases of BKVAN in EU4 and the UK (2022-2036)
  • Figure 23: Type-specific Cases of HSCT in EU4 and the UK (2022-2036)
  • Figure 24: Total Cases of BKHC in EU4 and the UK (2022-2036)
  • Figure 25: Grade specific Cases of BKHC in EU4 and the UK (2022-2036)
  • Figure 26: Total Cases of BK Viremia in Kidney Transplant Patients in Japan (2022-2036)
  • Figure 27: Total Cases of BKVAN in Japan (2022-2036)
  • Figure 28: Classification-specific Cases of BKVAN in Japan (2022-2036)
  • Figure 29: Type-specific HSCT Cases in Japan (2022-2036)
  • Figure 30: Total Cases of BKHC in Japan (2022-2036)
  • Figure 31: Grade-specific Cases of BKHC in Japan (2022-2036)
  • Figure 32: Total market size of BKV Infection in the 7MM, in USD million (2022-2036)
  • Figure 33: Total market size of BKVAN in the 7MM, in USD million (2022-2036)
  • Figure 34: Market Size of BKVAN by Therapies in the 7MM, in USD million (2022-2036)
  • Figure 35: Total market size of BKHC in the 7MM, in USD million (2022-2036)
  • Figure 36: Market Size of BKHC by Therapies in the 7MM, in USD million (2022-2036)
  • Figure 37: Total Market Size of BKVAN in the US, in USD million (2022-2036)
  • Figure 38: Market Size of BKVAN by Therapies in the US, in USD million (2022-2036)
  • Figure 39: Total Market Size of BKHC in the US, in USD million (2022-2036)
  • Figure 40: Market Size of BKHC by Therapies in the US, in USD million (2022-2036)
  • Figure 41: Total Market Size of BKVAN in EU4 and the UK, in USD million (2022-2036)
  • Figure 42: Market Size of BKVAN by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Figure 43: Total Market Size of BKHC in EU4 and the UK, in USD million (2022-2036)
  • Figure 44: Market Size of BKHC by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Figure 45: Total Market Size of BKVAN in Japan, in USD million (2022-2036)
  • Figure 46: Market Size of BKVAN by Therapies in Japan, in USD million (2022-2036)
  • Figure 47: Total Market Size of BKHC in Japan, in USD million (2022-2036)
  • Figure 48: Market Size of BKHC by Therapies in Japan, in USD million (2022-2036)
  • Figure 49: HTA
  • Figure 50: 7MM HTA Bodies
  • Figure 51: The US Healthcare Programs
  • Figure 52: Reimbursement Process of Germany
  • Figure 53: Reimbursement Process of France
  • Figure 54: Reimbursement Process of Italy
  • Figure 55: Reimbursement Process in Spain
  • Figure 56: Reimbursement Process in the United Kingdom
  • Figure 57: UK MHRA Approval Through IRF
  • Figure 58: Reimbursement Process in Japan
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!